161 related articles for article (PubMed ID: 11562275)
1. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.
Ganguly AK; Doll RJ; Girijavallabhan VM
Curr Med Chem; 2001 Oct; 8(12):1419-36. PubMed ID: 11562275
[TBL] [Abstract][Full Text] [Related]
2. Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Taveras AG; Kirschmeier P; Baum CM
Curr Top Med Chem; 2003; 3(10):1103-14. PubMed ID: 12769711
[TBL] [Abstract][Full Text] [Related]
3. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
4. Farnesyl transferase inhibitors as anticancer agents.
Haluska P; Dy GK; Adjei AA
Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Dempke WC
Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
[TBL] [Abstract][Full Text] [Related]
6. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
7. [New anticancer molecules: drugs for tomorrow?].
Lavelle F
Bull Cancer; 1999 Jan; 86(1):91-5. PubMed ID: 10029711
[No Abstract] [Full Text] [Related]
8. Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes.
Mirza UA; Chen G; Liu YH; Doll RJ; Girijavallabhan VM; Ganguly AK; Pramanik BN
J Mass Spectrom; 2008 Oct; 43(10):1393-401. PubMed ID: 18438977
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA; Awada A; Cutler DL; de Jonge MJ; Luyten GP; Faber MN; Statkevich P; Sparreboom A; Verweij J; Hanauske AR; Piccart M;
J Clin Oncol; 2001 Feb; 19(4):1167-75. PubMed ID: 11181683
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors.
Hahn SM; Bernhard E; McKenna WG
Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
[TBL] [Abstract][Full Text] [Related]
11. Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.
Njoroge FG; Vibulbhan B; Pinto P; Strickland CL; Bishop WR; Kirschmeir P; Girijavallabhan V; Ganguly AK
Bioorg Med Chem; 2003 Jan; 11(1):139-43. PubMed ID: 12467716
[TBL] [Abstract][Full Text] [Related]
12. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.
Strickland CL; Weber PC; Windsor WT; Wu Z; Le HV; Albanese MM; Alvarez CS; Cesarz D; del Rosario J; Deskus J; Mallams AK; Njoroge FG; Piwinski JJ; Remiszewski S; Rossman RR; Taveras AG; Vibulbhan B; Doll RJ; Girijavallabhan VM; Ganguly AK
J Med Chem; 1999 Jun; 42(12):2125-35. PubMed ID: 10377218
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
de Bono JS; Tolcher AW; Rowinsky EK
Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
[TBL] [Abstract][Full Text] [Related]
14. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
Njoroge FG; Taveras AG; Kelly J; Remiszewski S; Mallams AK; Wolin R; Afonso A; Cooper AB; Rane DF; Liu YT; Wong J; Vibulbhan B; Pinto P; Deskus J; Alvarez CS; del Rosario J; Connolly M; Wang J; Desai J; Rossman RR; Bishop WR; Patton R; Wang L; Kirschmeier P; Ganguly AK
J Med Chem; 1998 Nov; 41(24):4890-902. PubMed ID: 9822558
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
16. Farnesyl transferase inhibitors in myeloid malignancies.
Lancet JE; Karp JE
Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
